Table 2.

Sensitivity, specificity, and positive predictive value (PPV) of treatment (chemotherapy, surgery, radiotherapy, bone marrow transplant (BMT)) data abstracted from cancer registry (California Surveillance Program), OHSPD/hospitalization discharge, and SEER-Medicare data, compared to treatment abstracted from medical records among B-cell NHL cases diagnosed in Los Angeles County (2004–08).

	Overall				DLBCL				FL				CLL/SLL
Treatment	CSP N=695	OSHPD N=665	Medicare N=401	Combined N=698	CSP N=243	OSHPD N=235	Medicare N=133	Combined N=243	CSP N=167	OSHPD N=162	Medicare N=97	Combined N=167	CSP N=105	OSHPD N=98	Medicare N=70	Combined N=105
Chemotherapy
Sensitivity (%)	74	65	80	92	88	67	76	97	65	59	70	90	34	57	94	81
Specificity (%)	99	72	51	56	67	100	*	67	100	68	90	70	100	86	52	63
PPV (%)	100	94	91	93	100	100	100	100	100	92	98	95	100	91	80	83
Surgery
Sensitivity (%)	73	22	52	83	84	41	63	83	76	10	52	81	31	12	50	54
Specificity (%)	76	90	74	61	75	84	63	61	45	89	77	36	92	99	87	86
PPV (%)	68	60	61	60	63	58	49	51	67	56	80	65	57	75	62	56
Radiotherapy
Sensitivity (%)	67	11	41	77	61	12	32	71	61	3	40	75	50	*	100	100
Specificity (%)	99	97	89	91	100	96	86	89	99	98	87	92	99	*	93	96
PPV (%)	95	57	49	75	100	62	47	77	96	33	46	75	50	*	25	33
BMT
Sensitivity (%)	42	98	87	98	25	96	88	96	*	*	*	*	*	*	*	*
Specificity (%)	100	98	98	98	100	98	99	98	*	*	*	*	*	*	*	*
PPV (%)	100	87	72	83	100	85	88	85	*	*	*	*	*	*	*	*

^*insufficient number of cases receiving treatment to calculate

CLL/SLL: Chronic lymphocytic leukemia/small lymphocytic lymphoma. DLBCL: Diffuse large B-cell lymphoma. FL: Follicular lymphoma.